Results 121 to 130 of about 3,893,535 (160)

Therapy-related myeloid neoplasms following peptide receptor radionuclide therapy for neuroendocrine neoplasms: case series reporting characteristics and outcomes from single-centre experience. [PDF]

Endocr Oncol
Chow W, Wen I, Mok C, Huang K, Stevenson W, Roach PJ, Bailey DL, Diakos CI, Clarke SJ, Pavlakis N, Chan DL.   +10 more
europepmc   +1 more source

Intra-arterial peptide receptor radionuclide therapy (IA-PRRT) in patients with SSTR-expressing neuroendocrine neoplasms: short- and long-term safety and efficacy for up to 13 years. [PDF]

Theranostics
Zhang J, Mensel B, Baum RP.
europepmc   +1 more source

SSTR-directed peptide receptor radionuclide therapy for recurrent meningiomas: analysis of safety, efficacy and prognostic factors. [PDF]

Eur J Nucl Med Mol Imaging
Hasenauer N, Müller M, Hänscheid H, Serfling SE, Michalski K, Heinrich M, Polat B, Buck AK, Werner RA, Hartrampf PE.   +9 more
europepmc   +1 more source

Editorial: Women in radionuclide therapy: 2023

Frontiers in Nuclear Medicine
Egesta Lopci, Federica Matteucci
doaj   +1 more source

Peptide Receptor Radionuclide Therapy in Patients with Advanced, Recurrent or Progressive Meningioma: An Updated Systematic Review and Meta-Analysis. [PDF]

Cancers (Basel)
Muoio B, Iacovitti CM, Bosetti DG, Sansovini M, Cuzzocrea M, Paone G, Treglia G.   +6 more
europepmc   +1 more source

Peptide Receptor Radionuclide Therapy with Lu-177-DOTATATE and Monitoring with Somatostatin Receptor PET/CT in Patients with Advanced Differentiated Thyroid Carcinoma. [PDF]

Mol Imaging Biol
Kunte SC, Wenter VU, Holzgreve A, Sheikh GT, Widjaja L, Gildehaus FJ, Lindner S, Schirrmacher R, Spitzweg C, Auernhammer CJ, Werner RA, Zacherl MJ.   +11 more
europepmc   +1 more source

Considerations for Establishing Peptide Receptor Radionuclide Therapy: A Nationally Coordinated, Collaborative, and Equitable Service for New Zealand. [PDF]

World J Nucl Med
Steyn R, Henderson A, Wells K, Mead T, Rennie Y, Hull A, Meredith L, Sullivan M, Simmers S, Davidson J, Hauraki T, Damianovich D, Boyle V, Lawrence B.   +13 more
europepmc   +1 more source

AIMN, ITANET, SIE joint position paper for the recognition, prevention and management of NET carcinoid syndrome and crises during peptide receptor radionuclide therapy. [PDF]

Eur J Nucl Med Mol Imaging
Laudicella R, Faggiano A, Pirro V, Durmo R, Salsi P, Modica R, Urso L, Grana CM, Sances D, Rinzivillo M, Albertelli M, Spada F, Partelli S, Ferraù F, Fazio N, Tafuto S, Maccauro M, Bartolomei M, Panzuto F, De Rimini ML, Lastoria S, Filice A.   +21 more
europepmc   +1 more source

The PANEN nomogram: clinical decision support for patients with metastatic pancreatic neuroendocrine neoplasm referred for peptide receptor radionuclide therapy. [PDF]

Front Endocrinol (Lausanne)
Singh A, Sanduleanu S, Kulkarni HR, Langbein T, Lambin P, Baum RP.   +5 more
europepmc   +1 more source

Impact of functionality and grading on survival in pancreatic neuroendocrine tumor patients receiving peptide receptor radionuclide therapy. [PDF]

Front Endocrinol (Lausanne)
Mathew A, Kersting D, Fendler WP, Braegelmann J, Fuhrer D, Lahner H.   +5 more
europepmc   +1 more source